Clinical Trials Logo

Clinical Trial Summary

The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses for 14 consecutive days.


Clinical Trial Description

This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients with MS. Up to 55 untreated primary and secondary progressive MS patients will be enrolled, to obtain a total of 48 completed subjects (9 active, 3 placebos per group), allowing for dropouts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05029609
Study type Interventional
Source Tiziana Life Sciences, PLC
Contact Venkat S Renukuntla, MBBS, MPH
Phone +1267-810-9994
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date October 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Recruiting NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Not yet recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Not yet recruiting NCT04998812 - A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy Phase 4
Recruiting NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Not yet recruiting NCT04990219 - A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis Phase 1
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Active, not recruiting NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4
Completed NCT02232061 - Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks Phase 4
Recruiting NCT03983681 - Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS N/A
Enrolling by invitation NCT04676204 - Relationship Between Oral DMT Burden and Adherence in MS
Recruiting NCT03424733 - Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects Phase 4
Active, not recruiting NCT03122652 - Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome Phase 3